JP2016527202A5 - - Google Patents

Download PDF

Info

Publication number
JP2016527202A5
JP2016527202A5 JP2016519586A JP2016519586A JP2016527202A5 JP 2016527202 A5 JP2016527202 A5 JP 2016527202A5 JP 2016519586 A JP2016519586 A JP 2016519586A JP 2016519586 A JP2016519586 A JP 2016519586A JP 2016527202 A5 JP2016527202 A5 JP 2016527202A5
Authority
JP
Japan
Prior art keywords
amount
compound
cancer
administration
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016519586A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016527202A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/041643 external-priority patent/WO2014200969A2/en
Publication of JP2016527202A publication Critical patent/JP2016527202A/ja
Publication of JP2016527202A5 publication Critical patent/JP2016527202A5/ja
Pending legal-status Critical Current

Links

JP2016519586A 2013-06-10 2014-06-10 癌の治療方法 Pending JP2016527202A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361833186P 2013-06-10 2013-06-10
US61/833,186 2013-06-10
PCT/US2014/041643 WO2014200969A2 (en) 2013-06-10 2014-06-10 Methods of treatment of cancer

Publications (2)

Publication Number Publication Date
JP2016527202A JP2016527202A (ja) 2016-09-08
JP2016527202A5 true JP2016527202A5 (enExample) 2017-07-20

Family

ID=52022914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016519586A Pending JP2016527202A (ja) 2013-06-10 2014-06-10 癌の治療方法

Country Status (4)

Country Link
US (1) US20170035917A1 (enExample)
EP (1) EP3008212A4 (enExample)
JP (1) JP2016527202A (enExample)
WO (1) WO2014200969A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2924597A1 (en) 2013-09-19 2015-03-26 The Research Foundation For The State University Of New York Methods and materials for treating diabetes or liver steatosis
JP6793180B2 (ja) * 2015-03-27 2020-12-02 ザ リサーチ ファウンデーション フォー ザ ステイト ユニバーシティ オブ ニューヨーク 癌を治療するための方法および物質
US10639322B2 (en) 2015-03-27 2020-05-05 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
US12287389B1 (en) * 2015-07-31 2025-04-29 Fonar Corporation Method and system for monitoring effectiveness of a treatment regimen
RS67792B1 (sr) 2016-12-01 2026-03-31 Regeneron Pharma Radio-obeležena anti-pd-l1 antitela za imuno-pet snimanje
BR112019016336A2 (pt) 2017-02-10 2020-03-31 Regeneron Pharmaceuticals, Inc. Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
CN110997013B (zh) 2017-07-24 2022-09-20 瑞泽恩制药公司 抗cd8抗体和其用途
WO2019213024A1 (en) * 2018-04-30 2019-11-07 Integral Molecular, Inc. Glucose transporter 4 antibodies, methods of making the same, and uses thereof
CN109053782B (zh) * 2018-08-09 2020-01-17 潍坊博创国际生物医药研究院 多功能靶向免疫小分子抗癌药枸橼酸Bestazomib及其制备方法与应用
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100111856A1 (en) * 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
SI2318419T2 (sl) * 2008-06-17 2025-10-30 Takeda Pharmaceutical Company Limited Spojine boronat estra in njihovi farmacevtski sestavki
WO2012027379A2 (en) * 2010-08-24 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
JP2013542187A (ja) * 2010-09-21 2013-11-21 ジーイー・ヘルスケア・リミテッド 新規放射性トレーサー
AU2011339929B2 (en) * 2010-12-06 2017-05-11 Tom C. Tsang Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer
AU2012298794A1 (en) * 2011-08-23 2013-04-04 Infinity Pharmaceuticals, Inc. Biomarkers predictive of therapeutic responsiveness to HSP90 inhibitors and uses thereof
EP4706663A3 (en) * 2011-08-30 2026-05-20 Trustees Of Tufts College FAP-ACTIVATED PROTEASOME INHIBITORS USED TO TREAT SOLID TUMORS
CN104039328B (zh) * 2011-11-11 2018-10-09 米伦纽姆医药公司 对蛋白酶体抑制剂的反应的生物标记

Similar Documents

Publication Publication Date Title
US11707539B2 (en) FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto
US11730736B2 (en) Anticancer agents
JP2014510728A5 (enExample)
JP7169297B2 (ja) 再発膠芽腫（ｒｇｂｍ）の治療方法
RU2762193C2 (ru) Применение антагонистов рецептора ep4 для лечения nash-ассоциированного рака печени
JP2015536964A5 (enExample)
JP2010270124A5 (enExample)
RU2019142507A (ru) Композиции, способы и системы для синтеза и применение визуализирующих средств
JP2015212268A5 (enExample)
JP2014513089A5 (enExample)
JP2012255026A5 (enExample)
JP2011529968A5 (enExample)
JP2015522033A5 (enExample)
MX2013013014A (es) Metodo para el tratamiento de tumores solidos avanzados.
JP2014512355A5 (enExample)
CN105452258A (zh) 使用双核金(i)化合物用于癌症治疗的方法
JP2019530706A5 (enExample)
JP2018531605A5 (enExample)
EP4578461A3 (en) Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
JP2014530181A5 (enExample)
TW201141472A (en) Method to treat small cell lung cancer
JP7568309B2 (ja) 癌を処置する方法
JP2015515974A5 (enExample)
TWI856060B (zh) 口服二氧戊環核苷酸與抗pd1或抗pdl1單株抗體併用治療肝癌之方法
CN105616411A (zh) 治疗结肠癌的组合物及其应用